Arjun Goyal | Harvard Innovation Labs
Skip to content

Arjun Goyal

Co-Founder & Managing Director, Vida Ventures

Industry Expert

Arjun Goyal
Dr. Arjun Goyal is a Co-Founder and Managing Director of Vida Ventures, a leading US-based life sciences venture capital firm with approximately $1.7 billion in AUM. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Affini-T and Centessa Pharmaceuticals (NASDAQ: CNTA) and has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer). Before co-founding Vida Ventures in 2017, Arjun was a life sciences investor at 5AM Ventures. Arjun received his B.Sc. in Medical Science, Diploma in French and his MBBS degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his M.Phil. in Bioscience Enterprise from University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work including the American Australian Association Education Fellowship, Robert Kaplan Harvard Business School Life Science Fellowship, Oxford Clarendon Scholarship, Commonwealth Scholarship and Gates Cambridge Scholarship. He is a co-inventor on one patent and had served on the editorial board of an international scientific journal. He serves on the Committee for the American Australian Association Education Fellowship.

Biotech & Life Sciences, Healthcare, Venture Capital

More Experts View All